Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced its third-quarter financial results for 2025. The company reported operating revenue of 814 million yuan for the first nine months, representing a year-on-year decline of 34.35%. Net loss attributable to shareholders of the listed company stood at 136 million yuan, while net loss excluding non-recurring gains and losses reached 179 million yuan. Basic loss per share was 0.3013 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments